• Rapid test Supplier
  • Rapid Influenza A/B Antigen Test Kit | Fast & Accurate Diagnostic Solution

Iuch . 20, 2025 21:33 Back to list

Rapid Influenza A/B Antigen Test Kit | Fast & Accurate Diagnostic Solution

Gaobeidian PRISES Biotechnology Co., Ltd

Global leader in rapid diagnostic solutions

Phone

0086-(0)312-2930588

Email

export@prises.cn

Mobile

0086-15910623759

Address

No.136, Shiji West Road, Gaobeidian City, 074000, Hebei Province, P.R. China

Visit Our Website

Product Overview

The Flu A B Influenza Virus Ag Diagnostic Rapid Test Kit is an in vitro diagnostic test utilizing immunochromatographic technology. Designed for qualitative determination of influenza type A and type B virus infection, this test delivers results in just 8 minutes using nasopharyngeal swab specimens from symptomatic patients.

As the demand for accurate influenza a/b antigen test solutions grows worldwide, our influenza a/b antigen test kit provides healthcare professionals with a reliable tool for rapid diagnosis. The importance of distinguishing between Influenza A and B strains is critical for appropriate patient management and epidemiological surveillance.

Learn More About Our Product

Industry Trends & Market Analysis

The global market for rapid influenza diagnostic tests is experiencing substantial growth, with an estimated CAGR of 6.8% from 2023 to 2030. This expansion is driven by increased influenza prevalence, technological advancements in test kits, and growing awareness of early diagnosis.

Our Flu A B Influenza Virus Ag Diagnostic Rapid Test Kit is developed in response to the increasing need for point-of-care testing solutions that deliver laboratory-quality results in clinical settings, pharmacies, and even at home.

Technical Specifications & Performance Data

Understanding the technical parameters is essential for selecting the right diagnostic solution. Our influenza a/b antigen test kit offers exceptional performance metrics:

Performance Comparison

Parameter Our Product Industry Average
Detection Time 8 minutes 10-15 minutes
Sensitivity (Influenza A) 96.4% 90-95%
Sensitivity (Influenza B) 95.2% 88-94%
Specificity (Overall) 98.7% 96-98%
Storage Temperature 2-30°C 2-8°C
Sample Type Nasopharyngeal Swab Varies

Application Scenarios

The Flu A B Influenza Virus Ag Diagnostic Rapid Test Kit is designed for versatility across multiple healthcare settings:

Hospital Settings

Emergency departments utilize our influenza a/b antigen test for rapid triage of patients with influenza-like symptoms, enabling appropriate isolation decisions and treatment plans.

Clinics & Outpatient

Primary care physicians benefit from immediate results that inform antiviral prescription decisions during peak influenza seasons.

Long-Term Care

Nursing homes use our tests for early detection and containment of outbreaks among vulnerable populations.

School Health Programs

Educational institutions implement our influenza a/b antigen test kit for rapid screening to minimize absenteeism.

Professional FAQ

Q: What are the key components included in the Flu A B Influenza Virus Ag Diagnostic Rapid Test Kit?

A: Our test kit contains test cassettes, disposable sterile swabs, extraction buffer tubes, tube holders, and comprehensive instructions. Each component is quality-controlled for maximum reliability.

Q: How should I store the test kit to maintain its effectiveness?

A: Store the unopened kit at 2-30°C in a dry environment. Avoid freezing and exposure to direct sunlight. The kit remains stable for 24 months from the manufacturing date when properly stored.

Q: What is the scientific principle behind this influenza rapid test?

A: The test uses colloidal gold immunochromatography. The test strip contains monoclonal antibodies specific to influenza A and B nucleoproteins. When viral antigens are present, they bind to gold-conjugated antibodies and form visible lines on the membrane.

Q: How do you ensure quality control in manufacturing?

A: We implement a rigorous multi-stage QC process: raw material screening, in-process controls, and final product validation. Each batch undergoes performance testing against reference samples to ensure clinical accuracy.

Q: Is special training required to administer this test?

A: The test is designed for CLIA-waived complexity. Healthcare professionals can perform it after reviewing the included instructions. We also provide online training resources through our website.

Q: How does this influenza test handle emerging viral strains?

A: Our antibody selection targets highly conserved viral regions. We continuously monitor circulating strains and update our antigen targets when necessary. This commitment ensures sustained detection performance.

Q: What is the clinical significance of distinguishing Influenza A from B?

A: While treatment protocols are similar, distinguishing the type has epidemiological importance and can inform prognosis. Influenza A is associated with greater severity and pandemic potential, while Influenza B typically causes milder but more prolonged symptoms.

References & Expert Endorsements

The clinical value of rapid influenza diagnostic tests has been validated in numerous peer-reviewed studies:

Share

Next:

This is the last article

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


gdScottish Gaelic